Merz Pharma
German family-owned pharmaceutical company focused on medical aesthetics, neurological therapeutics, and consumer health and beauty.
Last updated August 26, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Merz Pharma GmbH & Co. KGaA, commonly known as Merz Pharma or Merz, is a privately held German pharmaceutical and healthcare group headquartered in Frankfurt am Main. Founded in 1908 by pharmacist and chemist Friedrich Merz, the company began as a small pharmaceutical manufacturer and gradually developed into a diversified international business. It remains family-owned and functions as the parent organization of three independently managed operating businesses: Merz Aesthetics, Merz Therapeutics, and Merz Consumer Care, whose corporate branding was supplemented by the name Merz Lifecare in 2023. The company’s most distinctive area is medical aesthetics. Merz Aesthetics develops and markets botulinum toxin products, dermal fillers, skin-quality treatments, and non-invasive aesthetic technologies. Its major brands include Xeomin, a botulinum toxin type A product; Belotero, a range of hyaluronic-acid dermal fillers; Radiesse, an injectable filler and biostimulator based on calcium hydroxylapatite; and Ultherapy, a device-based non-invasive skin-lifting platform acquired through the purchase of Ulthera. The aesthetics division sells primarily through physicians, clinics, and other professional healthcare channels rather than through conventional consumer retail. Merz Therapeutics concentrates on neurological and other specialty medicines. Its historical portfolio included memantine, an important treatment for moderate to severe Alzheimer’s dementia, while its later therapeutic focus has emphasized movement disorders such as dystonia and spasticity. The division also expanded through the acquisition of products for Parkinson’s disease and multiple sclerosis from Acorda Therapeutics in 2024. These activities complement Merz’s established expertise in botulinum toxin therapy, which has applications in both aesthetic medicine and neurological disorders. Merz Consumer Care, also associated with the Merz Lifecare identity, develops health, beauty, and wellness products. Its best-known brands include tetesept and Merz Spezial. Merz Spezial became particularly recognizable in Germany through beauty-care supplements and the positioning that beauty is supported from within. The consumer business gives the group a presence beyond prescription medicines, physician-administered procedures, and medical devices. Merz operates internationally through subsidiaries, production facilities, sales offices, collaborations, and distribution partners. Its manufacturing footprint has included sites in Reinheim and Dessau in Germany and in Racine County, Wisconsin, in the United States. The United States is especially important to the group’s aesthetics business and broader international development. In the late 2020 reorganization, Merz separated its activities into three more autonomous businesses and relocated the global Merz Aesthetics team from Frankfurt to Raleigh, North Carolina. The structure was intended to give each business clearer operational focus while retaining common ownership and oversight through the Merz board of partners and supervisory board. The company’s history reflects a recurring effort to balance traditional pharmaceuticals with newer growth areas. After memantine’s German patent expired in 2012, Merz accelerated investment in aesthetics and specialty neurology. Acquisitions of Bioform Medical, Neocutis, Anteis, and Ulthera strengthened its filler, dermatology, and device capabilities. Today, Merz presents itself as a specialized healthcare group rather than a broad mass-market pharmaceutical conglomerate, with its strongest strategic identities in medical aesthetics, neurological medicine, and consumer wellness.
History
Friedrich Merz established the company in Frankfurt am Main in 1908 as a pharmaceutical manufacturing business. At its foundation, the company already held intellectual-property protection for one of its developments. In 1909, it moved into a former cigarette factory, a site that later became associated with the company’s headquarters. Early products included a contraceptive preparation, mentholated refreshment cigarettes, and ointments for scaly skin conditions, reflecting the broad and experimental nature of its initial product development. World War II severely damaged the Frankfurt operation. Allied bombing destroyed much of the company’s buildings, but Merz had arranged for duplicate production machinery to be stored at Reinheim near Darmstadt. This precaution allowed the business to restart more quickly after the war and helped preserve its manufacturing capabilities. Merz entered cosmetics in 1953 with Placentubex, described in company history as an early anti-wrinkle product. From the 1960s, it expanded into beauty-care supplements and introduced Merz Spezial Dragees in 1964. Advertising in the 1970s and 1980s associated the product with the idea that natural beauty could be supported from within. During the 1970s, Merz also broadened its prescription portfolio, including products related to Parkinson’s disease and elevated blood lipids. A major therapeutic milestone came with the development of memantine. In 2002, Merz introduced the active ingredient for moderate to severe Alzheimer’s dementia. Memantine became a central product in the company’s pharmaceutical portfolio and helped establish Merz as a meaningful specialist in neurological medicine. Its German patent expired in 2012, although protection continued for a further period in the United States. The approaching loss of exclusivity encouraged Merz to accelerate diversification into medical aesthetics and other specialty areas. Merz’s aesthetic expansion began with the acquisition of U.S. company Bioform Medical in 2010 for approximately EUR 190 million. Bioform brought expertise in injectable fillers. In 2013, Merz acquired Swiss aesthetic-dermatology company Neocutis and also purchased Swiss filler producer Anteis. These transactions expanded the company’s portfolio in physician-administered aesthetic medicine. Merz had also entered the botulinum toxin market with a new-generation product in 2005. The product, later known as Xeomin, was positioned around its formulation without complexing foreign proteins. In 2014, Merz bought U.S. medical-device company Ulthera for a reported amount close to USD 600 million. The transaction gave Merz a non-invasive skin-lifting technology and broadened its aesthetic business beyond injectables. The company continued international expansion, including the establishment of a subsidiary in Thailand in 2015 and the development of sales offices, partnerships, and manufacturing capacity across Europe, North America, Latin America, and Asia-Pacific. Leadership also changed in 2012, when Jochen Hückmann, a grandson of the founder who had managed the business since the early 1970s, retired. Philip Burchard took over management. The transition occurred as Merz was reshaping its portfolio around international aesthetics and specialty neurology. The COVID-19 pandemic caused a sharp temporary disruption to aesthetic medicine in 2020. Clinics postponed cosmetic and medical procedures because of infection concerns and shortages of protective equipment. Later that year, Merz established a new organizational model based on three independently operating businesses: Merz Aesthetics, Merz Therapeutics, and Merz Consumer Care. The global aesthetics team moved from Frankfurt to Raleigh, North Carolina, reflecting the importance of the U.S. market and the division’s international commercial focus. In 2023, the consumer-health business began using Merz Lifecare as a corporate brand, while Merz Consumer Care GmbH remained the legal entity. Merz also announced an investment program for its Reinheim site, including modernization and changes to the production footprint. In 2024, Merz Therapeutics expanded its neurological portfolio by acquiring Inbrija and Ampyra from Acorda Therapeutics. The group continues to operate as a family-owned international healthcare company with activities spanning medical aesthetics, neurological therapeutics, and consumer wellness.
- 2024
Neurology portfolio expanded through Acorda acquisition
[1]Merz Therapeutics acquired Inbrija and Ampyra from Acorda Therapeutics.
- 2023
Merz Lifecare identity introduced
[1]The consumer-health operation began using Merz Lifecare as its corporate brand.
- 2020
Three-business operating structure created
[1]Merz reorganized its activities into Merz Aesthetics, Merz Therapeutics, and Merz Consumer Care.
- 2014
Ulthera acquired
[1]Merz acquired Ulthera, adding non-invasive skin-lifting medical technology to its aesthetics portfolio.
- 2013
Neocutis and Anteis acquisitions
[1]Merz acquired Swiss companies Neocutis and Anteis to strengthen aesthetic dermatology and filler products.
- 2012
Leadership transition
[1]Jochen Hückmann retired as managing director and Philip Burchard assumed leadership responsibilities.
- 2010
Bioform Medical acquired
[1]The acquisition expanded Merz’s presence in aesthetic dermal fillers.
- 2005
New-generation botulinum toxin launched
[1]Merz brought a botulinum toxin type A product to market, later marketed as Xeomin.
- 2002
Memantine development
[1]Merz developed and introduced memantine for moderate to severe Alzheimer’s dementia.
- 1964
Merz Spezial Dragees introduced
[1]Merz introduced its beauty-care dragees, which later became a major consumer brand in Germany.
Products and positioning
A specialized, premium healthcare group combining physician-led medical aesthetics, neurological therapeutics, and consumer health and beauty brands.
Botulinum toxin medicine · 2005
Xeomin
Xeomin is Merz’s botulinum toxin type A product for physician-administered therapeutic and aesthetic uses. Its formulation is positioned around the absence of complexing foreign proteins. Depending on the jurisdiction and indication, botulinum toxin products may be used for conditions involving abnormal muscle activity as well as for facial lines and wrinkles.
Dermal filler
Belotero
Belotero is a family of injectable hyaluronic-acid dermal fillers used in aesthetic medicine. The range is designed for different tissue depths and treatment objectives, including the correction of facial lines, folds, and volume-related concerns. It is distributed primarily through medical professionals and aesthetic clinics.
Dermal filler and biostimulator
Radiesse
Radiesse is an injectable aesthetic product based on calcium hydroxylapatite microspheres in a gel carrier. It is used by qualified practitioners for contouring, volume restoration, and selected indications involving the appearance of skin quality. The product is one of Merz Aesthetics’ principal injectable brands.
Non-invasive aesthetic medical device
Ultherapy
Ultherapy is a device-based aesthetic treatment platform acquired by Merz through its purchase of Ulthera. It uses focused ultrasound technology for non-invasive lifting and tightening applications. The platform broadened Merz’s aesthetics portfolio beyond injectable products and supports clinic-based procedures.
Neurological medicine · 2002
Memantine
Memantine was a major Merz therapeutic development for moderate to severe Alzheimer’s dementia. It became one of the company’s historically important medicines and helped establish its profile in neuroscience. Patent expiry later encouraged Merz to diversify toward aesthetics and additional specialty neurological products.
Parkinson’s disease medicine
Inbrija
Inbrija is an inhaled levodopa product for Parkinson’s disease. Merz Therapeutics acquired the product from Acorda Therapeutics in 2024, expanding Merz’s movement-disorder portfolio and its presence in treatments used alongside established Parkinson’s regimens.
Multiple-sclerosis medicine
Ampyra/Fampyra
Ampyra, known as Fampyra in some markets, is a sustained-release multiple-sclerosis tablet. Merz Therapeutics acquired the product from Acorda Therapeutics in 2024 as part of a broader expansion of its specialty-neurology portfolio.
Consumer health and wellness
tetesept
tetesept is a Merz consumer-health brand associated with wellness, personal care, and health products. It operates outside Merz’s prescription and physician-administered businesses and contributes to the group’s presence in retail and everyday health categories.
Beauty supplement · 1964
Merz Spezial
Merz Spezial is a beauty-care supplement brand launched in the 1960s. Its products have historically been positioned around nutritional support for skin, hair, and nails, and the brand became associated with German advertising emphasizing beauty from within.
Controversies
2024
FDA warning over Xeomin Instagram advertisement
The U.S. Food and Drug Administration objected to an Instagram advertisement featuring Nate Berkus in connection with Xeomin. The agency said that claims concerning the product’s rapid effects and unique benefits lacked adequate supporting evidence and that the presentation of risk information was insufficient, making the communication misleading.
2021
Merz sues MSN over generic Cuvposa application
Merz Pharmaceuticals filed a complaint against MSN Pharmaceuticals, alleging that MSN's application to market a generic version of Merz's Cuvposa would infringe Merz's drug patent. Merz sought an injunction against commercial manufacture, use, sale, offer for sale, or importation of the generic product.
Marketing campaigns
- 2023Christina Aguilera anti-wrinkle campaign
International
Christina Aguilera promoted Merz Aesthetics’ anti-wrinkle injection offering in a celebrity-led campaign.
Outcome. The campaign continued Merz Aesthetics’ strategy of pairing professional aesthetic treatments with high-profile entertainment figures.
- 2022Asia-Pacific ambassador program
Asia-Pacific
Merz Aesthetics announced Lee Min-ho, Kim Ha-neul, and Jeon So-min as ambassadors for the Asia-Pacific region.
Outcome. The initiative localized the division’s celebrity-led marketing approach for Asian markets.
- 2020Gwyneth Paltrow brand ambassador program
International
Gwyneth Paltrow became Merz Aesthetics’ first brand ambassador, extending the division’s consumer-facing communication around medical aesthetics.
Outcome. The partnership increased the visibility of Merz Aesthetics beyond professional clinic audiences.
- 2019Christie Brinkley aesthetic campaign
United States
Model Christie Brinkley promoted a non-invasive wrinkle-tightening procedure associated with Merz Aesthetics.
Outcome. The campaign illustrated Merz Aesthetics’ use of recognizable public figures to market physician-led aesthetic procedures.
- 1970Natural beauty comes from within
Germany
Merz Spezial Dragees were promoted during the 1970s and 1980s with a beauty-from-within positioning that linked the supplement brand to natural appearance and internal wellness.
Outcome. The slogan became a long-running part of Merz Spezial’s consumer-brand identity.
Brand decisions
2024
Acquire Inbrija and Ampyra from AcordaM&ABackground
Merz Therapeutics aimed to expand its specialty-neurology and movement-disorder portfolio.
Action taken
Merz acquired Inbrija for Parkinson’s disease and Ampyra, also known as Fampyra in some markets, for multiple sclerosis from Acorda Therapeutics.
Aftermath
The transaction added established neurological products to Merz Therapeutics’ portfolio.
2023
Rebrand consumer-health activities as Merz LifecareStrategyBackground
Merz sought a clearer corporate identity for its health, beauty, and wellness activities.
Action taken
Merz introduced Merz Lifecare as the corporate brand while retaining Merz Consumer Care GmbH as the legal company name.
Aftermath
The change separated the consumer-health identity from the broader Merz pharmaceutical group while preserving the existing legal structure.
2020
Create three independent business divisionsStrategyBackground
Merz needed a structure that could manage its increasingly distinct aesthetics, therapeutic, and consumer-health activities.
Action taken
The group established Merz Aesthetics, Merz Therapeutics, and Merz Consumer Care as independently operating businesses under the Merz parent structure.
Aftermath
The reorganization gave each business a clearer commercial and operational focus; the global aesthetics team also moved to Raleigh, North Carolina.
2014
Acquire UltheraM&ABackground
Merz wanted to broaden its aesthetics activities beyond injectable treatments and enter non-invasive medical technology.
Action taken
Merz acquired Ulthera, adding an ultrasound-based skin-lifting platform to its portfolio.
Aftermath
The acquisition established a larger role for Merz in device-based aesthetic procedures.
2010
Acquire Bioform MedicalM&ABackground
Merz sought to expand its medical-aesthetics business as it developed alternatives to reliance on traditional pharmaceutical products.
Action taken
Merz acquired U.S.-based Bioform Medical, a company specializing in aesthetic dermal fillers.
Aftermath
The transaction strengthened Merz’s injectable aesthetics platform and supported later portfolio expansion.
Recent events
- 2024
Merz Therapeutics acquires Inbrija and Ampyra from Acorda[1]
M&A · Product launch
Merz Therapeutics acquired the Parkinson’s disease medicine Inbrija and the multiple-sclerosis medicine Ampyra, also known as Fampyra in some markets, from Acorda Therapeutics.
- 2023
Merz introduces Merz Lifecare corporate identity[1]
Other
Merz introduced Merz Lifecare as the corporate brand for its consumer-health activities, while Merz Consumer Care GmbH remained the legal company name.
- 2020
Merz reorganizes the group into three independent businesses[1]
Other
Merz created separate operating businesses for aesthetics, therapeutics, and consumer care, while retaining the parent-company structure and centralized governance.
- 2020
Merz Aesthetics moves global team to Raleigh[1]
Other
The global Merz Aesthetics organization moved from Frankfurt to Raleigh, North Carolina, reinforcing the United States as a major center for the aesthetics business.
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/merz-pharma · Editorial policy · How profiles are compiled